• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Evolus

< Previous 1 2 3 4 Next >
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
November 07, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
November 06, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Participate in November Investor Conferences
November 01, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Report Third Quarter 2023 Results
October 25, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus to Participate in September Conferences
August 29, 2023
From Evolus
Via Business Wire
Tickers EOLS
News headline image
Evolus Announces Inducement Grants for New Chief Marketing Officer
August 23, 2023
From Evolus
Via Business Wire
Tickers EOLS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap